Hot Features
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhib... Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.49 | 10.9131403118 | 4.49 | 4.98 | 4.3 | 571764 | 4.56347819 | CS |
| 4 | 0.72 | 16.9014084507 | 4.26 | 4.98 | 4.225 | 346123 | 4.45506788 | CS |
| 12 | -0.91 | -15.4499151104 | 5.89 | 5.96 | 4.04 | 325005 | 4.8119642 | CS |
| 26 | 1.42 | 39.8876404494 | 3.56 | 6.45 | 3.285 | 432741 | 4.81023818 | CS |
| 52 | 1.39 | 38.7186629526 | 3.59 | 6.45 | 2.78 | 398763 | 4.10453583 | CS |
| 156 | 1.26 | 33.8709677419 | 3.72 | 6.45 | 2.3 | 362512 | 3.63908465 | CS |
| 260 | -16.52 | -76.8372093023 | 21.5 | 46.9099 | 2.3 | 733521 | 10.73929865 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.